The NICE reappraisal of biologics in 2005: what rheumatologists need to know.
作者信息
Bansback N J, Young A, Brennan A
出版信息
Rheumatology (Oxford). 2005 Jan;44(1):3-4. doi: 10.1093/rheumatology/keh364. Epub 2004 Aug 24.
PMID:15328422
Abstract
摘要
相似文献
1
The NICE reappraisal of biologics in 2005: what rheumatologists need to know.2005年英国国家卫生与临床优化研究所（NICE）对生物制剂的重新评估：风湿病学家需要了解的内容。
Rheumatology (Oxford). 2005 Jan;44(1):3-4. doi: 10.1093/rheumatology/keh364. Epub 2004 Aug 24.
2
Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.风湿病学的最新进展：治疗类风湿关节炎的生物制剂、银屑病关节炎的进展、系统性红斑狼疮中的自身抗体。
Clin Exp Dermatol. 2005 Mar;30(2):201-4. doi: 10.1111/j.1365-2230.2005.01731.x.
3
When is switching warranted among biologic therapies in rheumatoid arthritis?在类风湿关节炎中，何时需要在生物治疗之间进行转换？
Expert Rev Pharmacoecon Outcomes Res. 2012 Jun;12(3):319-33. doi: 10.1586/erp.12.27.
4
Biologic therapy for early rheumatoid arthritis: the latest evidence.早期类风湿关节炎的生物治疗：最新证据
Curr Opin Rheumatol. 2008 May;20(3):314-9. doi: 10.1097/BOR.0b013e3282f5fcf6.
5
[Biopharmaceuticals in the treatment of rheumatoid arthritis].[生物制药在类风湿关节炎治疗中的应用]
Ugeskr Laeger. 2008 Jun 9;170(24):2108-10.
6
An error in the revised anti-TNF therapy guidelines for adult RA.成人类风湿关节炎抗TNF治疗指南修订版中的一处错误。
Rheumatology (Oxford). 2006 Sep;45(9):1170. doi: 10.1093/rheumatology/kel197. Epub 2006 Jun 12.
7
Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.对安全性和成本的担忧使得生物制剂在类风湿关节炎治疗中的应用受到限制。
JAMA. 2003 Jun 25;289(24):3229-30. doi: 10.1001/jama.289.24.3229.
8
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.类风湿关节炎患者中抗TNF-α治疗反应的预测因素：来自英国风湿病学会生物制剂登记处的结果
Rheumatology (Oxford). 2006 Dec;45(12):1558-65. doi: 10.1093/rheumatology/kel149. Epub 2006 May 16.
9
Tuberculosis in the cytokine era: what rheumatologists need to know.细胞因子时代的结核病：风湿病学家需要了解的内容。
Arthritis Rheum. 2003 Aug;48(8):2085-91. doi: 10.1002/art.11134.
10
A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines.在三级临床护理中接受随访的强直性脊柱炎患者的一个主要亚组，根据当前指南需要抗肿瘤坏死因子α生物治疗。
Ann Rheum Dis. 2005 Sep;64(9):1383-4. doi: 10.1136/ard.2004.028423.
引用本文的文献
1
Differential expression of NK receptors CD94 and NKG2A by T cells in rheumatoid arthritis patients in remission compared to active disease.与活动期疾病相比，缓解期类风湿关节炎患者 T 细胞中 NK 受体 CD94 和 NKG2A 的差异表达。
PLoS One. 2011;6(11):e27182. doi: 10.1371/journal.pone.0027182. Epub 2011 Nov 15.
2
Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis.回顾性临床研究低剂量甲氨蝶呤和英夫利昔单抗治疗类风湿关节炎患者的疗效。
Clin Rheumatol. 2010 Jun;29(6):671-5. doi: 10.1007/s10067-010-1406-6. Epub 2010 Mar 4.
Zotero 插件